Program
inavolisib
Also written as “Inavolisib”, “Inavolisib (Dose #1)” and “Inavolisib (Dose #2)”.
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Neoplasms · Prostatic Neoplasms · Neoplasm Metastasis, led by Hoffmann-La Roche.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 2017 open or running | phase 3since Dec 2, 2019 | Dec 22, 2016 | Dec 31, 2026phase 1 · NCT03006172 |
Also a collaborator on its studies: Gilead Sciences and Pfizer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Dec 22, 2016.
- Mar 15, 2021Phase 2 study in Neoplasm MetastasisNCT04802759 · 316 planned · United States, Australia, Israel and more
- Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more
- Jun 11, 2021Phase 1 study in Colorectal NeoplasmsNCT04929223 · 542 planned · United States, Australia, Canada and more
- Dec 2, 2022Phase 3 study in Breast NeoplasmsNCT05646862 · 420 planned · United States, Argentina, Australia and more
- May 1, 20232 phase 3 studiesNCT05862285, NCT05894239
- Jul 4, 2024Phase 1 study in PIK3CA-Mutated CancersNCT06496568 · 30 enrolled · United States, Canada, South Korea
- Jan 14, 2025Phase 3 study in Breast NeoplasmsNCT06790693 · 450 planned · United States, Argentina, Australia and more
- Jun 26, 2025Phase 2 study in Breast NeoplasmsNCT07054190 · 120 planned · United States, Argentina, Brazil and more
- Aug 20, 2025Phase 1 study in Hepatic ImpairmentNCT07144111 · 27 enrolled · United States
- Dec 11, 2025Phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT07287150 · 100 planned · United States, Australia, Brazil and more
- Jan 6, 20262 phase 2 studiesNCT07323576, NCT07368998
- Feb 6, 2026Phase 2 study in Breast NeoplasmsNCT07405801 · 80 planned · United States, Argentina, Brazil and more
- Jul 20, 2026Phase 2 study in Breast NeoplasmsNCT07748208 · 40 planned · United States, Puerto Rico
- Nov 13, 2026Primary completion moved from 2026-12-31 to 2027-05-03Date moved laterphase 3 · +4 months · NCT05894239
Ahead
- Nov 13, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT05646862
- Dec 31, 2026Primary completion: phase 1 study in Breast NeoplasmsNCT03006172
- May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05894239
- Jul 21, 2027Primary completion: phase 1 study in PIK3CA-Mutated CancersNCT06496568
TargetBeta
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alpelisibrule | Novartis | phase 4 | 37 |
| tersolisib | Eli Lilly | phase 3 | 10 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| serabelisibrule | Takeda | phase 2 | 11 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| risovalisibrule | Haihe Biopharma | phase 2 | 4 |
| zovegalisibrule | relay-therapeutics-inc | phase 2 | 2 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | ensem-therapeutics | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07748208Breast Neoplasms · United States, Puerto Rico | 2 | Recruiting | Jun 15, 2029 | 40 |
| NCT07405801Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Dec 19, 2028 | 80 |
| NCT07368998Breast Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Oct 31, 2028 | 80 |
| NCT07323576Colorectal Neoplasms | 2 | Withdrawn | Mar 1, 2029 | 0 |
| NCT07287150Metastatic Castration-Resistant Prostate Cancer · United States, Australia, Brazil and more | 2 | Recruiting | Mar 31, 2028 | 100 |
| NCT07144111Hepatic Impairment · United States | 1 | Completed | Oct 13, 2026 | 27 |
| NCT07054190Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Jul 31, 2027 | 120 |
| NCT06790693Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jan 31, 2032 | 450 |
| NCT06496568PIK3CA-Mutated Cancers · United States, Canada, South Korea | 1 | Active, not recruiting | Jul 21, 2027 | 30 |
| NCT05894239Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | May 3, 2027 | 230 |
| NCT05862285Neoplasms · Belgium, Canada, China and more | 3 | Recruiting | Mar 1, 2033 | 200 |
| NCT05646862Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Nov 13, 2026 | 420 |
| NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Aug 31, 2030 | 542 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 28, 2028 | 176 |
| NCT04802759Neoplasm Metastasis · United States, Australia, Israel and more | 2 | Recruiting | May 30, 2029 | 316 |
| NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States | 2 | Completed | Dec 4, 2023 | 252 |
| NCT04589845Solid Tumors · United States, Australia, Belgium and more | 2 | Active, not recruiting | Sep 25, 2032 | 920 |
| NCT04191499Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 29, 2023 | 325 |
| NCT03424005Breast Neoplasms · United States, Australia, France and more | 2 | Recruiting | Sep 30, 2030 | 1,132 |
| NCT03006172Breast Neoplasms · United States, Canada, France and more | 1 | Active, not recruiting | Dec 31, 2026 | 200 |
How it is read
Names in the registry
- “Inavolisib”, 20 entries
- “Inavolisib (Dose #1)”, 1 entry
- “Inavolisib (Dose #2)”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 10 studies
- Colorectal Neoplasms, 2 studies
- Neoplasms, 1 study
- Prostatic Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.